Bexirestrant
A selective estrogen receptor degrader
| Bexirestrant | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | Selective estrogen receptor degrader |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Bexirestrant is a selective estrogen receptor degrader (SERD) that is being investigated for the treatment of hormone receptor-positive breast cancer. It is designed to bind to the estrogen receptor and promote its degradation, thereby inhibiting the growth of estrogen-dependent tumors.
Mechanism of Action[edit | edit source]
Bexirestrant functions by binding to the estrogen receptor (ER) and inducing a conformational change that targets the receptor for degradation. This process reduces the number of functional estrogen receptors available in the cell, thereby diminishing the estrogen signaling that can promote the growth of certain types of breast cancer. Unlike selective estrogen receptor modulators (SERMs), which block the receptor's activity, SERDs like bexirestrant lead to the receptor's destruction.
Clinical Development[edit | edit source]
Bexirestrant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with hormone receptor-positive breast cancer. These trials aim to determine the optimal dosing regimen and to compare its effectiveness with existing therapies such as fulvestrant, another SERD.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of bexirestrant includes its absorption, distribution, metabolism, and excretion. It is administered orally, and studies are ongoing to understand its bioavailability and half-life. The drug is metabolized in the liver, and its metabolites are excreted primarily through the feces.
Potential Benefits[edit | edit source]
Bexirestrant offers potential benefits over existing therapies by providing a more complete degradation of the estrogen receptor, which may lead to improved outcomes in patients with resistant forms of breast cancer. Its oral administration also offers a more convenient alternative to injectable therapies.
Side Effects[edit | edit source]
As with many cancer therapies, bexirestrant may have side effects. Commonly observed adverse effects in clinical trials include fatigue, nausea, and hot flashes. Ongoing studies are monitoring for any long-term effects and the overall safety profile of the drug.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
